Invicorp is commonly used for the symptomatic management of Erectile Dysfunction (ED) in adult males. The medication addresses the core functional problem: symptoms that interfere with daily functioning, specifically the persistent inability to achieve and sustain an erection firm enough for sexual intercourse. The treatment is relevant for addressing ED in situations involving neurogenic, vasculogenic, psychogenic, or mixed aetiology, and is applied across therapeutic domains involving localized vascular issues. It is applied when symptoms that create noticeable physiological strain interfere significantly with functional stability.

---

Management of Symptoms Resistant to Initial Support

The medication is applied when conditions are characterized by periods of heightened symptoms and are resistant to initial pharmaceutical intervention. The use is often relevant when symptoms are resistant to initial, less intensive forms of pharmaceutical support, offering a supportive option for continued management.

---

Support for Complex Clinical Aetiologies

Invicorp may provide relevant supportive relief across various underlying causes of ED. It is commonly used in challenging clinical settings, such as managing dysfunction following radical prostatectomy. This application contributes to easing discomfort and may assist with supportive relief when symptoms interfere with routine activities during symptomatic periods.

---

Quick Fact: Support for Resistant Manifestations

This therapy is commonly used across conditions where symptomatic management requires additional support beyond initial treatments.

Regulatory References

1. All Wales Therapeutics and Toxicology Centre (AWTTCC)

Invicorp (Aviptadil/Phentolamine mesilate) is licensed for use only in adult males aged 18 years and above. Regulatory documents generally restrict its use to a second-line treatment option, typically for patients whose condition has been unresponsive to initial pharmaceutical support, such as oral PDE5 inhibitors.

Use is contraindicated in several specific populations. This medicine must not be used by men with known hypersensitivity to the active ingredients or excipients. Absolute contraindications also apply to men with conditions predisposing to priapism, including leukaemia, multiple myeloma, or sickle cell anaemia/trait. Additionally, men with anatomical deformation of the penis, such as Peyronie’s disease or cavernosal fibrosis, and those with a penile implant are prohibited from use. A final absolute restriction applies to men currently taking anticoagulant agents (blood thinners) or men for whom sexual activity is medically inadvisable.

The label notes that no formal studies have established safety or efficacy in patients above 75 years or those with impaired hepatic or renal function. Use in children, adolescents, and females is not applicable or not recommended.

Interactions with other medicines and products

The official regulatory profile for this combination drug is defined by restrictions on co-administration, which stem from the potential for additive pharmacodynamic effects and the procedural constraints of the injection method.

Property	Official Interaction Status
Contraindicated Combinations	Co-administration is explicitly prohibited with all other treatments for erectile dysfunction and all anticoagulant agents.
Interaction Risk Basis	Additive vasoactive effects and increased localized bleeding risk at the injection site.

---

Mandatory Co-administration Restrictions

The regulatory label enforces a strict prohibition against using this product concurrently with any other treatment for erectile dysfunction. This constraint is established to mitigate the risk of severe additive vasoactive effects, which are a possibility with combined smooth-muscle relaxants.

A second core restriction involves anticoagulant agents. All medications used to reduce blood clotting are formally contraindicated for co-administration. This includes agents such as warfarin, heparin, and newer oral anticoagulants like dabigatran, rivaroxaban, and apixaban. This restriction directly addresses the pharmacodynamic risk of increased bruising, hematoma, or localized bleeding associated with the intracavernosal injection procedure.

Absence of Pharmacokinetic Interactions

The official prescribing information does not document any specific interactions mediated by major drug transporters or CYP enzymes. Furthermore, the regulatory documents confirm that no clinically significant interaction has been observed with the concomitant use of anti-hypertensive or other general cardiovascular medication.

How Invicorp Works

Invicorp modulates local hemodynamic processes through a complementary, dual-pathway mechanism involving its two active components.

The Phentolamine component initiates its action by functioning as a non-selective antagonist at Alpha-1 (alpha1) and Alpha-2 (alpha2) Adrenergic Receptors on the vascular smooth muscle. This receptor blockade directly counteracts constrictive signals mediated by norepinephrine, thereby inhibiting the sympathetic control pathway. This mechanism promotes arterial vasodilation, resulting in a substantial increase in blood inflow into the tissue.

Concurrently, Aviptadil acts as an agonist on the VPAC1 and VPAC2 Receptors, triggering an internal cellular cascade that elevates the concentration of cyclic adenosine monophosphate (cAMP). This molecular event causes a prolonged relaxation of the cavernosal smooth muscle tissue. This physiological change promotes the expansion of the tissue necessary to compress the surrounding venules, a process known as veno-occlusion, which modulates the rate of blood drainage. The synergy between increasing inflow and enhancing veno-occlusion coordinates the modulation of local hemodynamic processes.

How Invicorp is Used

Invicorp (Aviptadil / Phentolamine mesilate) is administered according to specific, standardized instructions. Its use is governed by a precise route, fixed dosage, and strict limits on frequency, ensuring a standardized approach to administration.

---

Administration Protocol

Instruction	Detail
Route of Administration	Intracavernosal Injection (ICI) into the corpus cavernosum.
Standard Dosing	The entire contents of one ampoule (Aviptadil 25 mcg / Phentolamine 2 mg). No dose titration is required.
Maximum Frequency	Not to exceed once daily or 3 times per week. A minimum of 24 hours must separate each dose.
Duration Guideline	The erection resulting from the injection should not exceed one hour.

---

Procedural and Population Requirements

Administration of Invicorp requires specialized adherence to procedural instructions. The first injections must be administered by medically trained personnel. Self-injection is only permitted after the patient has received proper training on the correct technique.

Crucially, the injection site and the side of the penis must be alternated with each use to support local tissue health. The injection must be placed into the dorsolateral aspect of the proximal third of the penis. The solution may be used directly from the refrigerator or warmed to room temperature prior to use.

Invicorp is not indicated for use in children and adolescents.

Research evidence / Overview of studies for Invicorp

---

Evidence for Symptomatic Management of Erectile Dysfunction (ED)

Research has explored the use of Invicorp in adult males with Erectile Dysfunction (ED), including cohorts presenting with mixed, vasculogenic, neurogenic, or psychogenic origins. The evidence base includes short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and mainly examined the achievement of an erection grade suitable for sexual intercourse, along with monitoring the recorded duration of the erection. Findings describe patterns related to the proportion of observed patients who met the study's primary physiological endpoint, but research provides limited information for long-term outcomes.

---

Evidence for ED Non-Responsive to Initial Treatment and Post-Surgical ED

Invicorp was also evaluated in research settings involving conditions where symptoms may vary in intensity and are resistant to initial pharmaceutical support, such as oral treatments. Studies explored the use of the agent in patients with ED following major surgery like radical prostatectomy. This evidence is derived primarily from large retrospective observational reviews and smaller open-label pilot studies, rather than large-scale RCTs. Research examined outcomes related to physical discomfort and the ability to resume penetrative sexual activity. The data show patterns related to use over defined time intervals, with large reviews reporting follow-up durations that averaged over a year.

---

Long-Term Research and Durability of Response

Follow-up durations were limited in the primary controlled trials, but evidence derived from observational settings evaluating daily-life functioning described mean observation periods of over one year in certain patient groups. However, long-term effects are not fully established. The evidence for continuous or long-term outcomes is limited, and there is limited information regarding the consistency of the observed physiological patterns over extended use.

---

Synthesis of Research Gaps and Remaining Uncertainty

Evidence highlights what is known—and what is still uncertain—about this combination agent. Key research limitations include the fact that results apply only to the populations studied. The lack of standardized formulations across different research settings was noted, which may impact the comparison of evidence. Furthermore, data show patterns related to high rates of treatment discontinuation, a general challenge for all intracavernosal therapies, which studies observed in the populations evaluated.

Key Studies & References

1. Efficacy and safety of aviptadil/phentolamine mesilate (Invicorp) in patients with erectile dysfunction following radical prostatectomy.
2. A single centre retrospective review of aviptadil/phentolamine intracavernosal combination for erectile dysfunction.
3. Intracavernosal pharmacotherapy for erectile dysfunction: current status and future prospects.
4. Aviptadil/phentolamine (Invicorp) - All Wales Therapeutics and Toxicology Centre (AWTTCC) Recommendation

Common questions about Invicorp (FAQ)

---

Q: Is Invicorp the same as other ED injections I've heard of?

According to official product information, Invicorp is a fixed-dose combination of two active ingredients: aviptadil and phentolamine mesilate. This dual-component approach distinguishes it from other injectable treatments that may use only a single active ingredient.

---

Q: Can Invicorp be used by people with high blood pressure?

Regulatory documents state that no clinically significant interaction has been observed when Invicorp is used with general anti-hypertensive (blood pressure) medications. However, the medicine must be used with caution in patients who have severe cardiovascular conditions. The suitability of this treatment for individuals with high blood pressure is evaluated by a healthcare provider.

---

Q: Does Invicorp affect fertility or sperm quality?

The official product information addresses fertility under its safety sections. Because the medicine is intended only for use in men, regulatory documents state that fertility information is 'Not relevant' to its prescribed use.

---

Q: Can I travel with Invicorp and keep it at the right temperature?

Yes, but strict storage is required. Official instructions state that Invicorp must be kept in a refrigerator between 2 C and 8 C and must not be frozen. While it can be briefly removed to warm to room temperature before use, the solution must be used within 24 hours of being taken out of refrigeration.

---

Q: What's the difference between Invicorp and Trimix?

Invicorp is officially a two-component product, containing aviptadil and phentolamine mesilate. In contrast, compounds often referred to as 'Trimix' typically contain three different active components. Information regarding the suitability of different treatments is provided by a healthcare professional.

---

Q: Can diabetes patients safely use Invicorp?

The medicine is generally indicated for erectile dysfunction from various causes, including neurogenic (nerve-related) issues. Its safety profile is defined by restrictions against conditions like priapism predisposition or anatomical deformations. The decision to use Invicorp is based on an evaluation of overall health criteria, which includes factors beyond a specific diagnosis like diabetes.

---

Q: Is it normal to feel a bit of pain or burning after injecting Invicorp?

Pain at the site of injection is listed in official regulatory documents as an uncommon side effect, meaning it may affect up to 1 in 1,000 people. Any persistent or unusual pain or discomfort should be mentioned to a healthcare provider.

---

Q: Can I use Invicorp if I have a history of heart attack or stroke?

Official information states that Invicorp must be used with caution in patients who have severe cardiovascular or cerebrovascular conditions, including a history of heart attack (myocardial infarction) or stroke. The full health history, including any previous heart or lung issues, is a factor considered during treatment evaluation.

---

Q: Are there any specific medical conditions that rule out using Invicorp?

Yes, official labeling lists several absolute contraindications. These include known hypersensitivity to the ingredients, conditions that predispose to a persistent erection (priapism, such as sickle cell disease or leukaemia), anatomical deformation of the penis (like Peyronie's disease), or the use of anticoagulant (blood thinning) agents.

---

Q: Does Invicorp cause any long-term problems if used regularly?

The official safety profile reports that the development of small nodules or fibrous tissue on the penis has been reported as a rare side effect following multiple injections. This rare risk is potentially related to the increased duration of use.

---

Q: Does Invicorp interact with common pain relievers like ibuprofen?

The regulatory information does not document any specific interactions between Invicorp and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. The primary restrictions involve a strict prohibition against using other ED treatments and all anticoagulant agents.

---

Q: Is it possible to become dependent on Invicorp for function?

The official product information notes that the potential for misuse or abuse of the medicine is a factor to consider. This caution applies especially to patients with a history of psychiatric disorder or addiction.

---

Q: Is Invicorp approved for use in older men (e.g., over 65)?

Invicorp is licensed for use only in adult males aged 18 years and above. However, the regulatory documents note that formal safety and efficacy studies have not been established in patients above the age of 75.

---

Q: Can Invicorp be used multiple times in one day?

No, the official administration protocol is strict regarding frequency. The injection must not exceed once daily, and a minimum of 24 hours must separate each dose.

---

Q: Is there a maximum number of times I can use Invicorp per month?

The official regulatory documents state that the injection frequency should not exceed 3 times per week. This frequency limit is stated to help reduce the risk of localized adverse effects.

---

Q: How do doctors monitor a patient's response to Invicorp?

The first injections must be administered by medically trained personnel. Before authorizing self-injection, patients must receive proper training on the correct technique. Patients are also instructed to immediately report any erection that lasts four hours or longer.

Invicorp requires strict temperature control to maintain its integrity, as mandated by regulatory authorities. The solution for injection must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F), and it must not be frozen. The ampoule can be brought to room temperature before use, but the contents must be used within 24 hours of being taken out of the refrigerator.

The medicine should be kept out of the sight and reach of children.

For disposal, do not throw away unused or expired product via wastewater or household waste. The used ampoule, syringe, and needle must be carefully placed in a needle container (sharps container) for disposal, in accordance with local requirements.